For the quarter ending 2025-09-30, KAPA had $2,541K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from common stock issued for cash in connection with the closing of the initial public offering | 0 | - |
| Proceeds from notes payable - officers | 0 | 0 |
| Payment of deferred offering costs | 0 | 0 |
| Proceeds from the sale and exercise of prefunded warrants | 0 | 3,058 |
| Proceeds from the equity line of credit | 3,379 | 223 |
| Net cash provided by financing activities | 3,379 | 3,281 |
| Debt discount amortization | 0 | 0 |
| Fair value of common shares issued in connection with the conversion of accounts payable | 0 | - |
| Fair value of warrants issued in connection with convertible notes payable | 0 | - |
| Vendor advances | 0 | - |
| Amortization of vendor advances | 660 | 1,298 |
| Fair value of vested restricted stock units | 70 | 153 |
| Prepaid expenses and other current assets | -64 | 50 |
| Accounts payable and accrued expenses | -274 | -316 |
| Net loss | -1,398 | -2,684 |
| Amortization of intangible asset | 40 | 80 |
| Net cash used in operating activities | -838 | -1,519 |
| Net increase in cash and cash equivalents | 2,541 | 1,762 |
| Cash and cash equivalents at beginning of period | 1,272 | - |
| Cash and cash equivalents at end of period | 5,575 | - |
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)